Pharmacology Quiz: Leukotriene Modifiers

20 questions · exam conditions

0:00

Leukotriene ModifiersQuestion 1 of 20

A 72-year-old patient with asthma requires a leukotriene modifier. The patient's medication list includes warfarin (CYP2C9 substrate), theophylline (CYP1A2 substrate), and amlodipine (CYP3A4 substrate). To minimize the risk of clinically significant pharmacokinetic drug interactions, which leukotriene modifier is the most prudent choice?

Zileuton

Montelukast

Zafirlukast

Zileuton extended-release

← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Leukotriene Modifiers

Practice Leukotriene Modifiers in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Leukotriene Modifiers, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

Zileuton
Montelukast (correct answer)
Zafirlukast
Zileuton extended-release

Explanation: This question requires comparing the drug interaction profiles of the leukotriene modifiers. Zileuton is a broad-spectrum CYP inhibitor (1A2, 2C9, 3A4) and would interact with all three of the patient's medications. Zafirlukast is a potent inhibitor of CYP2C9 and a moderate inhibitor of CYP3A4, posing a risk with warfarin and amlodipine. Montelukast, at therapeutic doses, does not cause clinically significant inhibition or induction of major CYP enzymes and is therefore the safest option in a patient on multiple medications metabolized by these pathways.

Question 2

Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are powerful mediators in asthma pathophysiology. Montelukast blocks the CysLT1 receptor, thereby attenuating many of their effects. Which of the following inflammatory processes is a key downstream effect of CysLT1 receptor activation that is effectively inhibited by montelukast?

Increased vascular permeability and plasma exudation, leading to airway edema. (correct answer)
Potent chemoattraction and activation of neutrophils.
Direct degradation of collagen in the bronchial basement membrane.
Inhibition of regulatory T-cell function in the airway mucosa.

Explanation: When approaching leukotriene receptor antagonist questions, focus on the specific inflammatory cascade effects that cysteinyl leukotrienes produce in asthma. These lipid mediators are key players in the allergic inflammatory response. Cysteinyl leukotrienes (LTC4, LTD4, LTE4) binding to CysLT1 receptors triggers several downstream effects, but their most clinically significant action is dramatically increasing vascular permeability. This leads to plasma protein extravasation into airway tissues, causing the characteristic airway edema seen in asthma. Montelukast effectively blocks this receptor, preventing this fluid leakage and reducing airway swelling. This is why answer A is correct. Let's examine why the other options miss the mark: B is incorrect because cysteinyl leukotrienes are not primarily neutrophil chemoattractants—they're more associated with eosinophil recruitment and smooth muscle contraction. C is wrong because leukotrienes don't directly degrade collagen; they're inflammatory mediators, not proteolytic enzymes. D is incorrect because CysLT1 activation doesn't primarily target regulatory T-cells—the leukotriene pathway focuses on immediate inflammatory responses rather than adaptive immune regulation. Remember that leukotriene receptor antagonists like montelukast are particularly effective for allergic asthma because they target the vascular permeability component of inflammation. When you see questions about these drugs, think "anti-edema" and "anti-inflammatory" rather than bronchodilation—that's what sets them apart from beta-agonists and helps explain their role in asthma management.

Question 3

Which of the following patient populations represents a clinical scenario where a leukotriene receptor antagonist is often considered a particularly suitable first-line or alternative controller therapy for asthma?

Patients with concomitant allergic rhinitis and mild persistent asthma. (correct answer)
Patients with severe, eosinophilic asthma refractory to high-dose ICS/LABA.
Patients with COPD-asthma overlap syndrome and a heavy smoking history.
Patients experiencing an acute, life-threatening asthma exacerbation.

Explanation: When approaching questions about leukotriene receptor antagonists (LTRAs) like montelukast, think about their unique pharmacological profile and clinical niche. LTRAs block cysteinyl leukotriene receptors, reducing both bronchoconstriction and inflammation, making them particularly valuable in specific patient populations. LTRAs shine in patients with allergic rhinitis and mild persistent asthma because leukotrienes play a key role in both conditions. These oral medications simultaneously address nasal congestion, rhinorrhea, and asthma symptoms, offering convenient dual-benefit therapy. For mild persistent asthma, LTRAs can serve as effective controller monotherapy, especially when inhaled corticosteroids (ICS) aren't tolerated or preferred. This makes option A correct. Option B is incorrect because severe, eosinophilic asthma refractory to high-dose ICS/LABA combinations requires more potent interventions like biologics (anti-IgE, anti-IL5) or systemic corticosteroids—LTRAs lack sufficient anti-inflammatory power for this scenario. Option C is wrong because COPD-asthma overlap with heavy smoking history primarily involves neutrophilic inflammation and structural changes that respond better to bronchodilators and ICS combinations. LTRAs have limited efficacy in COPD-dominant pathophysiology. Option D is incorrect because acute, life-threatening exacerbations require immediate bronchodilation with short-acting beta-agonists and systemic corticosteroids. LTRAs are controller medications with gradual onset—they're not rescue therapy. Remember: LTRAs are most valuable when you need dual respiratory benefits (asthma + rhinitis) or when seeking oral controller alternatives for mild disease. They're not powerful enough for severe asthma or acute situations.

Question 4

A 4-year-old child with a history of recurrent viral-induced wheezing is prescribed montelukast oral granules. What is the primary therapeutic goal of using this non-steroidal agent in this specific pediatric population?

To provide rapid relief of acute wheezing episodes.
To reverse long-term airway remodeling.
To eliminate the need for any future inhaled corticosteroid use.
To reduce the frequency and severity of inflammatory exacerbations. (correct answer)

Explanation: When you encounter questions about leukotriene receptor antagonists like montelukast in pediatric asthma management, focus on their role as anti-inflammatory controller medications rather than rescue treatments. Montelukast works by blocking leukotriene receptors, which prevents the inflammatory cascade triggered by leukotrienes—key mediators in asthma pathophysiology. In children with viral-induced wheezing, the primary goal is prophylactic: reducing baseline airway inflammation to prevent future exacerbations and minimize their severity when they do occur. This makes option D correct—montelukast serves as a controller medication that dampens the inflammatory response over time. Option A is incorrect because montelukast has slow onset (takes days to weeks for full effect) and provides no immediate bronchodilation. Rapid relief requires beta-2 agonists like albuterol. Option B misrepresents montelukast's capabilities—while it reduces ongoing inflammation, it cannot reverse structural changes like smooth muscle hypertrophy or basement membrane thickening that characterize airway remodeling. Option C is problematic because montelukast doesn't eliminate the need for inhaled corticosteroids; in fact, many patients require both medications, and inhaled corticosteroids remain first-line controller therapy for persistent asthma. Remember this distinction: rescue medications (short-acting beta-2 agonists) treat acute symptoms, while controller medications (inhaled corticosteroids, leukotriene antagonists, long-acting beta-2 agonists) prevent future problems. Montelukast is particularly useful in viral-induced wheezing because viruses trigger leukotriene release, making leukotriene blockade especially relevant in this population.

Question 5

A 55-year-old patient with persistent asthma is poorly controlled on a medium-dose inhaled corticosteroid. The patient also takes warfarin for atrial fibrillation and has moderately elevated baseline ALT levels. A physician considers adding a leukotriene modifier. Which agent presents the most significant management challenges due to this patient's comorbidities and concomitant medications?

Montelukast
Zafirlukast
Zileuton (correct answer)
Omalizumab

Explanation: Zileuton presents the most challenges. First, it is associated with hepatotoxicity and requires routine monitoring of liver function tests (LFTs); the patient's elevated baseline ALT is a significant concern. Second, zileuton is an inhibitor of CYP1A2 and CYP3A4, and can increase the concentration of warfarin (metabolized by CYP2C9, CYP1A2, and CYP3A4), elevating the risk of bleeding. Montelukast has minimal effects on LFTs and fewer significant drug interactions. Zafirlukast can cause rare hepatotoxicity and inhibits CYP2C9, which would also be a concern with warfarin, but zileuton's combination of frequent hepatotoxicity and enzyme inhibition makes it the most challenging option. Omalizumab is a biologic agent with a different risk profile not focused on hepatic metabolism or CYP interactions.

Question 6

A new investigational drug, "Dualukast," is a potent antagonist at both the CysLT1 receptor and the BLT1 receptor (for LTB4). Compared to the 5-lipoxygenase inhibitor zileuton, what is a primary theoretical advantage of Dualukast's mechanism of action?

It would have a superior safety profile by avoiding inhibition of the 5-LOX enzyme. (correct answer)
It would provide more effective bronchodilation than albuterol.
It would also block the production of pro-inflammatory prostaglandins.
It would only need to be administered via inhalation for targeted effects.

Explanation: When comparing leukotriene-targeting drugs, focus on the distinction between enzyme inhibition versus receptor antagonism and their respective therapeutic implications. Dualukast's dual receptor antagonism at CysLT1 and BLT1 receptors offers a significant safety advantage over zileuton's enzyme inhibition approach. Zileuton blocks 5-lipoxygenase (5-LOX), which prevents formation of all leukotrienes but also disrupts the entire arachidonic acid pathway at that branch point. This broader enzymatic inhibition can lead to more systemic effects and potential toxicity, which is why zileuton requires regular liver function monitoring. In contrast, Dualukast selectively blocks specific receptors without interfering with enzyme function, allowing normal metabolic processes to continue while preventing inflammatory signaling. This targeted approach typically results in fewer adverse effects and a superior safety profile, making choice A correct. Choice B is incorrect because neither leukotriene modifiers nor Dualukast would provide superior bronchodilation compared to albuterol, a direct β2-agonist that rapidly relaxes bronchial smooth muscle. Choice C misrepresents the mechanism—blocking leukotriene receptors doesn't affect prostaglandin production, which occurs through a different enzymatic pathway (cyclooxygenase). Choice D makes an unfounded assumption about delivery route; receptor antagonists can be formulated for various administration methods, and the mechanism doesn't inherently require inhalation. Remember: receptor antagonists generally have better safety profiles than enzyme inhibitors because they're more selective and don't disrupt entire metabolic pathways. This principle applies broadly across pharmacology.

Question 7

A 19-year-old with exercise-induced bronchoconstriction (EIB) is prescribed montelukast 10 mg daily. During a strenuous workout, he experiences acute wheezing and shortness of breath. He immediately takes his daily montelukast tablet, but his symptoms do not resolve. The failure of montelukast to provide immediate relief in this situation is because it:

primarily works by preventing, not reversing, mast cell degranulation.
lacks direct bronchodilatory properties and has a slow onset of action. (correct answer)
requires co-administration with a beta-agonist to be activated.
is rapidly metabolized by the liver before it can reach the airways.

Explanation: Leukotriene modifiers like montelukast are controller medications, not rescue medications. Their mechanism involves blocking the pro-inflammatory and bronchoconstrictive effects of leukotrienes, which is a process that is prophylactic in nature. They do not cause rapid relaxation of airway smooth muscle (bronchodilation) and have a slow onset of action, making them ineffective for treating acute bronchospasm. Rescue inhalers like albuterol are required for acute symptom relief.

Question 8

A clinical trial compares the effects of zileuton and montelukast on inflammatory biomarkers in asthmatic patients' urine. A significant reduction in the urinary concentration of which of the following biomarkers would be expected in the zileuton group but NOT in the montelukast group?

Leukotriene E4 (LTE4)
Prostaglandin D2 (PGD2)
Leukotriene B4 (LTB4) metabolites (correct answer)
Histamine metabolites

Explanation: Zileuton inhibits the 5-lipoxygenase enzyme, which is upstream in the leukotriene synthesis pathway. This blocks the production of all leukotrienes, including LTB4 and the cysteinyl leukotrienes (LTC4, LTD4, LTE4). Montelukast is a CysLT1 receptor antagonist, blocking the effects of cysteinyl leukotrienes but not their synthesis. Therefore, only zileuton would reduce the synthesis and subsequent excretion of LTB4 metabolites. Both drugs would lead to a functional reduction in CysLT effects, but only zileuton blocks LTB4 synthesis directly. Neither drug directly affects prostaglandin or histamine pathways.

Question 9

According to the Global Initiative for Asthma (GINA) guidelines, for an adult with moderate persistent asthma who is symptomatic despite using a short-acting beta-agonist as needed, which of the following is the preferred initial controller therapy?

A daily leukotriene receptor antagonist (LTRA).
A long-acting beta-agonist (LABA) as monotherapy.
A low-dose inhaled corticosteroid (ICS). (correct answer)
A daily oral dose of zileuton.

Explanation: Major asthma guidelines, including GINA, recommend a low-dose inhaled corticosteroid (ICS) as the preferred initial controller therapy for patients with persistent asthma (Step 2 and beyond). LTRAs are considered an alternative, but generally less effective, controller therapy. LABA monotherapy is contraindicated due to an increased risk of asthma-related death. Zileuton is typically reserved as an alternative or add-on therapy in later steps of asthma management, not as a first-line controller.

Question 10

A 28-year-old patient is prescribed zafirlukast for chronic asthma management. Which instruction from the pharmacist is most critical for ensuring optimal bioavailability of this specific medication?

Take the medication with a high-fat meal to enhance its absorption.
The medication can be taken at any time, with or without food.
Swallow the tablet whole; do not crush or chew it.
Take the medication on an empty stomach, 1 hour before or 2 hours after a meal. (correct answer)

Explanation: The bioavailability of zafirlukast is significantly reduced (by approximately 40%) when taken with food. Therefore, to ensure consistent and maximal absorption, it is crucial to administer the drug on an empty stomach. The standard recommendation is to take it at least one hour before or two hours after eating. Taking it with a high-fat meal would worsen, not enhance, absorption. While swallowing tablets whole is generally good practice, the food-drug interaction is the most critical pharmacokinetic parameter for this specific agent.

Question 11

A 45-year-old patient with nasal polyps and adult-onset asthma reports severe wheezing and facial flushing after taking aspirin for a headache. This presentation suggests aspirin-exacerbated respiratory disease (AERD). The therapeutic rationale for initiating a leukotriene receptor antagonist is to directly counteract the increased production of:

pro-inflammatory prostaglandins resulting from COX-2 induction.
cysteinyl leukotrienes from shunting of arachidonic acid metabolism. (correct answer)
bradykinin due to mast cell degranulation triggered by aspirin.
IgE antibodies specific to a metabolite of aspirin.

Explanation: In AERD, inhibition of the COX-1 pathway by NSAIDs like aspirin shunts arachidonic acid metabolism down the 5-lipoxygenase pathway. This leads to a significant overproduction of cysteinyl leukotrienes (LTC4, LTD4, LTE4), which are potent bronchoconstrictors and inflammatory mediators, causing the characteristic respiratory symptoms. Leukotriene receptor antagonists (e.g., montelukast) or synthesis inhibitors are a cornerstone of AERD management because they directly block this key pathogenic pathway.

Question 12

A patient with asthma is being treated with a leukotriene modifier that is administered once daily in the evening, is available as a chewable tablet for children, and carries a black box warning regarding mood and behavior changes. Which drug is this patient taking?

Zileuton
Zafirlukast
Montelukast (correct answer)
Cromolyn

Explanation: This combination of features is unique to montelukast. It is dosed once daily, comes in various formulations including chewable tablets and granules for pediatric use, and is the only drug in its class with a black box warning for serious neuropsychiatric events. Zafirlukast is dosed twice daily and has food restrictions. Zileuton is dosed multiple times a day and is associated with liver toxicity. Cromolyn is an inhaled mast cell stabilizer.

Question 13

A patient taking zafirlukast for asthma is prescribed a new medication for a fungal infection. Which of the following antifungals would prompt the most significant concern for a potential drug-drug interaction?

Nystatin
Amphotericin B
Micafungin
Fluconazole (correct answer)

Explanation: When evaluating potential drug interactions with asthma medications like zafirlukast, you need to focus on cytochrome P450 enzyme systems. Zafirlukast is a leukotriene receptor antagonist that's metabolized primarily by CYP2C9 and CYP3A4 enzymes. The key concern is finding medications that significantly inhibit these same pathways. Fluconazole (D) creates the most significant interaction risk because it's a potent inhibitor of both CYP2C9 and CYP3A4 enzymes. When fluconazole blocks these metabolic pathways, zafirlukast clearance decreases dramatically, potentially leading to toxic accumulation. This can result in elevated liver enzymes and serious hepatotoxicity, which is already a rare but serious side effect of zafirlukast alone. The other antifungals pose minimal interaction risks. Nystatin (A) works topically and has virtually no systemic absorption, so it doesn't affect hepatic metabolism. Amphotericin B (B) primarily undergoes non-enzymatic degradation rather than CYP metabolism, making clinically significant interactions unlikely. Micafungin (C) is an echinocandin that doesn't significantly inhibit CYP enzymes at therapeutic doses. Remember that azole antifungals (fluconazole, itraconazole, ketoconazole) are notorious CYP inhibitors and frequently cause drug interactions. When you see azoles paired with medications metabolized by CYP enzymes, always consider interaction potential. For zafirlukast specifically, monitor liver function closely if azole therapy is necessary, and consider alternative antifungals when possible.

Question 14

A 68-year-old patient with severe asthma is managed with a high-dose inhaled corticosteroid/long-acting beta-agonist, tiotropium, and oral theophylline. The physician decides to add zafirlukast. Two weeks later, the patient presents to the emergency department with nausea, tremor, and palpitations. An ECG shows sinus tachycardia. These new symptoms are most likely caused by:

Zafirlukast-induced hepatotoxicity leading to systemic symptoms.
A direct agonistic effect of zafirlukast on cardiac beta-receptors.
Inhibition of theophylline metabolism by zafirlukast. (correct answer)
An additive anticholinergic effect with tiotropium.

Explanation: The patient's symptoms (nausea, tremor, palpitations, tachycardia) are classic signs of theophylline toxicity. Theophylline is metabolized primarily by CYP1A2 and to a lesser extent by CYP3A4. Zafirlukast is a known inhibitor of CYP2C9 and CYP3A4. By inhibiting theophylline's metabolism, zafirlukast can cause a significant increase in serum theophylline concentration, leading to toxicity. This pharmacokinetic interaction is the most plausible explanation for the acute onset of these specific symptoms after the addition of zafirlukast.

Question 15

A 15-year-old with allergic rhinitis and mild persistent asthma is prescribed montelukast. The patient's parents call the clinic one month later, concerned about recent episodes of irritability, vivid nightmares, and new depressive thoughts. Which of the following is the most appropriate initial action?

Reassure the parents that these are common, transient side effects.
Discontinue montelukast and consider an alternative therapy. (correct answer)
Refer the patient for a psychiatric evaluation before changing medications.
Decrease the dose of montelukast to see if the symptoms resolve.

Explanation: Montelukast carries a black box warning for serious neuropsychiatric events, including depression, behavioral changes, and suicidal ideation. Given the patient's new and concerning symptoms, the most appropriate initial action is to discontinue the suspected causative agent and select an alternative treatment for their asthma and rhinitis, such as an inhaled corticosteroid or an intranasal steroid. Reassurance is inappropriate given the severity of the potential side effects. A psychiatric evaluation may be necessary, but the first step is to remove the likely iatrogenic cause. Decreasing the dose may not resolve the issue and unnecessarily prolongs the patient's exposure.

Question 16

Zileuton
Montelukast (correct answer)
Zafirlukast
Zileuton extended-release

Question 17

Zileuton exerts its therapeutic effect by directly inhibiting the 5-lipoxygenase enzyme. This action specifically prevents the conversion of which substrate to its immediate product, thereby halting the synthesis of all leukotrienes?

Arachidonic acid to 5-hydroperoxyeicosatetraenoic acid (5-HPETE) (correct answer)
Phospholipids to arachidonic acid
5-HPETE to Leukotriene A4 (LTA4)
Leukotriene A4 (LTA4) to Leukotriene C4 (LTC4)

Explanation: When you encounter questions about leukotriene synthesis inhibitors like zileuton, focus on understanding the sequential steps of the 5-lipoxygenase pathway and where specific drugs intervene. The 5-lipoxygenase pathway begins when arachidonic acid is released from membrane phospholipids. The 5-lipoxygenase enzyme catalyzes the very first step: converting arachidonic acid to 5-HPETE (5-hydroperoxyeicosatetraenoic acid). This is the committed step that initiates leukotriene synthesis. By blocking this initial conversion, zileuton prevents formation of all downstream leukotriene products, making choice A correct. Choice B describes phospholipase A2 activity, which occurs upstream of the leukotriene pathway and releases arachidonic acid from membrane phospholipids. This isn't where zileuton acts. Choice C represents the second step of leukotriene synthesis, where 5-HPETE is converted to LTA4 (leukotriene A4). While this is still catalyzed by 5-lipoxygenase, it's not the primary therapeutic target since blocking here wouldn't prevent 5-HPETE formation. Choice D describes the conversion of LTA4 to LTC4, which is catalyzed by leukotriene C4 synthase, not 5-lipoxygenase. Remember that zileuton is unique among anti-leukotriene drugs because it directly inhibits the enzyme (5-lipoxygenase) rather than blocking leukotriene receptors. Always identify the first committed step in a biosynthetic pathway—blocking early steps typically provides the most comprehensive therapeutic effect by preventing all downstream products.

Question 18

Increased vascular permeability and plasma exudation, leading to airway edema. (correct answer)
Potent chemoattraction and activation of neutrophils.
Direct degradation of collagen in the bronchial basement membrane.
Inhibition of regulatory T-cell function in the airway mucosa.

Question 19

It would have a superior safety profile by avoiding inhibition of the 5-LOX enzyme. (correct answer)
It would provide more effective bronchodilation than albuterol.
It would also block the production of pro-inflammatory prostaglandins.
It would only need to be administered via inhalation for targeted effects.

Question 20

Patients with concomitant allergic rhinitis and mild persistent asthma. (correct answer)
Patients with severe, eosinophilic asthma refractory to high-dose ICS/LABA.
Patients with COPD-asthma overlap syndrome and a heavy smoking history.
Patients experiencing an acute, life-threatening asthma exacerbation.